Introduction
This is the 18th annual report of the European IVF-monitoring Consortium (EIM) under the umbrella of ESHRE containing the data on ART reported by 39 participating European countries in 2014 (Supplementary Data).
Seventeen previous reports, all published in 'Human Reproduction' (https://www.eshre.eu/Data-collection-and-research/Consortia/EIM/ Publications.aspx), covered treatment cycles from 1997 to 2013. As in previous reports, the printed version contains the five most relevant tables. Nineteen additional Supplementary tables are available online. The settings of the data are consistent with those published in the previous reports, allowing good comparison with earlier trends.
Materials and Methods
Aggregated data on various forms of ART were provided by 39 European countries, covering the following treatment modalities: IVF, ICSI, frozen embryo replacement (FER), egg donation (ED), IVM, and pooled data on preimplantation genetic testing (PGT) and frozen oocyte replacement (FOR). In addition, data on IUI using either husband's/partner's semen (IUI-H) or donor semen (IUI-D) were included. The report includes treatments started between 1 January and 31 December in 2014. Data on pregnancies and deliveries are derived from follow-up of the treatments performed in 2014. Each national register is informed about the need to obtain signed informed consent prior to the initiation of infertility treatment from each infertile individual for whom data have to be reported to the national registry.
For the collection of the data, the national representatives of 41 countries were asked to fill out questionnaires and data were transmitted through a software package, specially designed for the requirements of this data collection (Dynamic Solutions, Barcelona, Spain) . The same sets of data as in 2013, consisting of six different modules, were requested as in 2014. The software performs all calculations automatically and evaluates the plausibility of all results. If inconsistencies are detected, the administrator of the ESHRE central office (V.G.) contacts the national representative for clarifications.
The data were assembled similarly as in the previous reports making the results comparable. As usual, footnotes to the tables provide additional information on diverging results reported by individual countres, when applicable.
The terminology used was based on the glossary of The International Committee for Monitoring Assisted Reproductive Technology (ICMART) (Zegers-Hochschild et al., 2017) .
Results

Participation and data completeness
In Table I the number of institutions or clinics offering ART services and those performing IUI are listed together with all available treatment modalities. In comparison to the 2013 data not only the numbers of reporting clinics has increased (1169 in 2013 to 1279 in 2014, +9.5%), but also the overall number of reported treatments (686 271 in 2013 to 776 556 in 2014, +13.1%) . Among the 51 European countries, nine are not members of the EIM Consortium (Supplementary Table SI) , most being very small countries not offering ART services. Bosnia-Herzegovina resumed their participation. Armenia became a member of the EIM Consortium but has not yet provided any data to the Consortium, and neither did Turkey and Slovakia. Among the 42 members, 39 have sent in their data (92.9%) and in 14 countries (35.8%) all ART centres have reported complete data sets. Currently, 1280 clinics report their data (87.6% of all known clinics in Europe, 85.4% in 2013) . The European countries with the largest treatment numbers in 2014 are Spain (109 275 treatments), Russia (94 985), France (90 434) and Germany (81 177).
Reporting methods and size of the clinics
Among the countries with complete coverage of data reporting there is a clear preponderance of registries to which reporting is compulsory (13 out off 15), although among those countries with incomplete data sets six require compulsory data reporting by the local national health authorities (Supplementary Table SIII) . Mainly in countries with incomplete coverage, personal initiatives continue to play a major role (seven countries), as do medical organizations (in 13 countries).
Aggregate data submission by single ART institutions to the respective national registries is still the most commonly used method (8 in 17 countries with full coverage, 16 in 25 countries with incomplete coverage) (Supplementary Table SIII) . Individual cycle reporting is being carried out in seven countries with full data coverage and in nine countries with incomplete coverage of the reported cycles.
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Number of treatment cycles per technique and availability
In 2014 a total number of 776 556 treatment cycles were reported to EIM (90 285 more than in 2013, +13.1%) ( Table I ). Since the beginning of its activities EIM has now recorded a total of more than 8 million treatments with ART leading to the birth of nearly 1.5 million infants (Table II Among the total of 508 433 fresh treatments (ICSI+IVF), 71.3% were performed with ICSI, showing a rise of +1.66% compared with 2013. The preponderance of ICSI over conventional IVF has become more pronounced in recent years ( Fig. 1) .
As in previous years, with 192 017 treatments, FER is rapidly gaining ground (+24.1%) but the relative proportion to fresh treatments was stable (37.8% in 2014 and 38.3% in 2013), Switzerland being the country with the highest proportion of FER (82.1%) and Serbia with the lowest (1.8%).
Availability of ART in any particular country is calculated by dividing the number of treatment cycles by the number of women of reproductive age (15-45 years) (Supplementary Table SIV) . Availability can only be calculated in the 14 countries with full coverage. In those 14 countries a huge variability in availabilty was observed, ART being most available in Denmark, and least available in Malta. As a result the proportion of newborns resulting from ART born in Denmark was 6.4% of all newborns in that country and 0.9% in Malta. Table III lists pregnancy rates (PR) and delivery rates (DR) after IVF or ICSI and after FER (regardless of the technique). As in previous reports, data on the number of initiated cycles were incomplete. For that reason we calculated outcome data per aspiration. All 39 participating countries were able to provide pregnancy and delivery data after aspiration, but seven countries failed to provide those after FER (completeness rate: 82.5%). Complete coverage data on both pregnancies and deliveries were provided by 14 countries (Supplementary Table SIV ). As shown in Table II , the number of infants born after any method was not provided in five countries (completeness rate: 87.5%). As in earlier reports, the PR and DR (all treatment modalities included) varied significantly from one country to another, PR ranging from 17.1 to 53.1%, DR ranging from 7.9 to 37.8% (except Hungary, reporting no deliveries per aspiration for ART). After FER the DR varied between 5.1 and 41.2%.
Pregnancies and deliveries after treatment
Taking all data together (Table II) , the PR per aspiration were similar in both IVF and ICSI, 29.3 and 27.2%, respectively, as were the DR, 22.3 and 20.1%, respectively. The PR and DR after thawing of embryos were 27.6 and 19.3%, respectively. The total number of ART infants born in 2014 after all techniques amounted to 170 163, a marked increase of 13.8% (total number of children born in 2013: 149 466).
For the first time, information about 'freeze all' cycles was collected (Supplementary Table SV) . Freeze all was carried out at the oocyte level in eight countries (20.5%), and at the embryonic level in 18 countries (46.1%). The registered data demonstrate that freeze all was the decision in 3080 (0.6%) of all IVF+ICSI cycles (at the oocyte level) and in 23 567 (4.8%) at the embryonic level.
Detailed accounts of cycle numbers, aspirations, transfers, pregnancies, and deliveries in IVF, ICSI and FER (after both IVF and ICSI) are given in the Supplementary Tables SV-SVII. ED data are given by 22 of 39 participating countries (55%) (Supplementary Table SVIII) . In most of the other countries this technology is not being performed for legal reasons. Most donation cycles were carried out in Spain, Russia and the Czech Republic, with 12 632, 3672 and 4924 cycles, respectively. Some of 29 965 ED cycles were carried out with freshly collected oocytes (22, 100%), some with frozen oocytes (FOR). PR were only available per embryo transfer (ET), but were considerably higher with freshly donated oocytes (50.3%) than after thawing of oocytes (37.7%). The differences among countries were considerable, ranging between 15.1 and 66.7%. A total of 17 259 deliveries were counted, which considerably exceeds the 11 861 deliveries counted in 2013 (+45.5%). This increment is due to higher numbers of reported deliveries in Spain (+45.1%) and Russia (+47.4%).
Age distribution
As in previous reports, the age distribution of women treated with IVF and ICSI varied among different countries (Supplementary Tables SIX  and SX) . Not all countries were able to provide data on the age distribution in ICSI and in IVF, some because no IVF treatments were carried out. The highest percentage of women aged 40 years and older undergoing aspiration for IVF was found in Greece (as in 2013), whereas the highest percentage of women aged <34 years was found in Ukraine and in Poland (as in 2013) . Also in ICSI the highest percentage of women aged 40 years and older undergoing aspiration was found in Greece, whereas the highest percentage of women undergoing aspiration aged <34 years was recorded in Albania (as in 2013).
Overall the well known age-dependent decline of the reported PR and DR was very similar in IVF and ICSI, but the differences among countries were considerable. Although the age-related decline was present in FER cycles as well (Supplementary Table SXI) , the outcome data of FER were generally higher than in the fresh cycles. In contrast, in ED donation cycles (Supplementary Table SXII ) age of the recipient women did not impact on PR or on DR.
Number of embryos transferred and multiple births
The number of embryos transferred after IVF and ICSI together are presented in Table IV . Although the specific number of elective single embryo transfers cannot be identified, the number of transfers of only one embryo per cycle continues to rise, whereas the number of transfers of three or more embryos per cycle decreases (Fig. 2) . The number of countries with more than 50% single embryo transfers has risen from six in 2013 to eight in 2014 (Austria, Belgium, Czech Republic, Denmark, Finland, Iceland, Poland and Sweden). The countries with more than 40% of transfers with three embryos were BosniaHerzegovina (Republik of Srpska), Lithuania and Serbia. In Greece 7.4% of transfers were carried out with four or more embryos.
Additional details about the pregnancy and delivery data are given in Supplementary Tables SXIII and SXIV. The recorded incidence of pregnancy loss was 15.5% after IVF + ICSI (in 2013: 16.8%) and 18.6% after FER (in 2013: 19.8%). The recorded loss to follow-up was 9.9% after IVF + ICSI (in 2013: 8.3%) and 7.3% after FER (in 2013: 9.7%).
Twin and triplet deliveries were similar after IVF+ICSI treatments and after FER. Those countries with the highest proportion of single embryo transfers also had the lowest twin and triplet DR (the lowest in Sweden, 4.2 and 0.1%, respectively) in fresh cycles. The countries still proceeding with the transfer of three or more embryos in fresh cycles present with DR of twins ranging between 18.2% (Lithuania) and 29.6% (Bosnia-Herzegovina, Republik of Srpska), and with DR of triplets ranging between 1.2% (Greece) and 1.8% (Lithuania). Interestingly, Lithuania with higher numbers of transfers of three and more embryos in fresh cycles did not report any twin or triplet deliveries after FER.
Regarding ED, of 15 749 deliveries with information regarding multiplicity, 3675 were twins (23.3%) and 56 were triplets (0.4%) (data not presented in tables).
Perinatal risks and complications
Data on premature deliveries were availabe from 20 European countries. The incidence of premature delivery is listed according to the number of newborns in Supplementary Total rates refer to these countries where all data were reported for the given technique: † ART infants also include ED. For IVF and ICSI there were for Belarus, Croatia, Czech Republic, Finland, Germany, Greece, Latvia, Lithuania, Macedonia, Poland, Portugal, Romania, Russia and Spain respectively 75, 3, 6, 886, 10, 22, 8, 49, 38, 15, 6, 62, 1019 and 2 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants.
For FER there were for Austria, Czech Republic, Finland, France, Greece, Latvia, Lithuania, Macedonia, Poland, Romania and Russia, respectively, 488, 7, 694, 5, 8, 45, 2, 3, 28, 21 and 283 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For ED there were for Czech Republic, Finland, Greece, Latvia, Romania, Russia and Spain respectively 5, 149, 2, 6, 7, 126 and 1022 deliveries with unknown outcome. These were accepted as singletons to calculate the ART infants. For PGD there were for Latvia, Russia and Spain, respectively, 1, 25 and 841 deliveries with unknown outcome. These were accepted as singleton to calculate the ART infants. this item the premature DR (<37 weeks) of singleton pregnancies calculated per embryo transfer has remained similar to the premature DR of twin pregnancies (Fig. 3) .
Complications of various steps of ART, such as ovarian hyperstimulation syndrome (OHSS), haemorrhage, infections and maternal deaths, were reported by 31 countries (Supplementary Table SXVI) . With 2040 cases, OHSS was the most common reported complication of ART (incidence rate: 0.3% of all reported cycles). Other complications were much rarer, such as haemorrhage (0.1% of all treatment cycles), infections (0.01%) and maternal death (3 per 700 000 treatment cycles). Two cases of maternal death occurred in the context of pregnancy and delivery (aortic dissection in a pregnant Turner syndrome patient, amniotic fluid embolism). Another patient died of sudden heart failure 1 day before oocyte collection.
Foetal reductions were reported from 16 countries and were performed in 0.07% of all treatment cycles. Most foetal reductions were reported in the UK, Spain and Russia.
PGT/PGT-A PGT (PGT for monogenic disorders or structural rearrangements) and PGT-A (PGT for aneuploidy) activities were reported from 22 countries (20 in 2013, 19 in 2012) . The number of treatment cycles was 15 894 (2.05% of all ART treatments, Table I (Table I) , 2655 transfers, 790 pregnancies and 548 deliveries. The vast majority was carried out in Italy (1639 treatments) and in Spain (845 treatments). Table SXVII) and using donated semen (IUI-D, Supplementary Table SXVIII) were collected by 1364 institutions in 25 and 21 countries, respectively. Spain was the most active country in both treatment modalities. All together, 120 789 treatments with IUI-H resulted in 9533 deliveries (7.92%), whereas 49 163 treatments with IUI-D in 5061 deliveries (10.3%), similar to results reported in 2013. In all three age groups most pregnancies led to singleton deliveries (90.3% in IUI-H, 92.2% in IUI-D). The twin and triplet DR were generally low (Table V) , depending on the age of the treated patient and were similar to those reported in previous years (twin deliveries: 8.8 and 7.3%, respectively; triplet deliveries: 0.4 and 0.3%, respectively).
IUI
Data on IUI with husband semen (IUI-H, Supplementary
Sum of fresh and FER ('cumulative') DR
Supplementary Table SXIX provides us with an estimate (not a true rate, as the data set presented here is cross-sectional) of a cumulative DR, calculated from the fresh embryo transfers and those carried out after thawing. The data are presented based on the sum of the fresh and FER deliveries and the number of aspirations of the same year as the denominator. As no data on deliveries were available from Hungary, we were able to calculate cumulative DR from the data of 38 countries (35 countries in 2013) . Whereas in all data taken together the DR after the fresh cycle amounted to 20.5%, the cumulative DR was 28.1% (a rise of 1.2% compared to 2013). The countries with the highest benefit resulting from FER were Finland (+16.0%), Ukraine (+15.2%), Albania (+14.6%), the Czech Republic (+14.0%), Kazakhstan (+13%) and Sweden (+13.0%). The countries with the lowest benefit resulting from FER were Malta (+0%) and Macedonia (+0.3%).
Cross-border reproductive care
Fifteen countries reported data on cross-border patients: Albania, Belarus, Croatia, Denmark, Finland, Greece, Iceland, Macedonia, Malta, Poland, Portugal, Serbia, Slovenia, Spain and Switzerland. A total of 17 160 cycles were reported, 36.4% of which involved IVF/ICSI with the couple's own gametes, while 45.6% were ED and 17.4% were IVF or ICSI with semen donation. Additionally, 8021 IUI with sperm donation were registered. Information regarding the countries of origin was very incomplete and not reliable enough to obtain any conclusive information. The main reasons reported by patients were to have access to a technique not legally available in their home countries (53.2%) or to seek a higher quality treatment (17.0%).
Discussion
This is the 18th annual report of the combined activities of the European national registries collecting data on ART. The EIM Consortium, from 1997 to 2014, has reported on more than 8 million treatments (8 010 527) leading to the birth of nearly 1.5 million infants (1 478 452). A comprehensive review of the first 15 years of EIM (from 1997 to 2011) was recently published (Ferraretti et al., 2017) .
The present collected data summarizes the totality of the data collections provided by 39 European countries (38 in 2013), as BosniaHerzegovina joined the consortium. Data are still not available from Azerbaijan, Georgia and Kosovo. Slovakia and Turkey are members of the EIM Consortium, but were not able to participate. Another group of small European countries never participated in the Consortium, such as Andorra, Armenia, Liechtenstein, Luxemburg, Monaco, San Marino and The Vatican, most of them not offering independent ART services. The level of completeness at the national level has risen to 92.9%, and at the level of the reporting clinics to 87.5%, both a substantial increase as compared to previous years.
Fourteen countries were able to provide data sets for all registered clinics (Supplementary Table SIV) , but the quality of data sets varies much from one country to another. A good example are discrepancies on the definition of a treatment: initiated treatment or collection of oocytes. Whereas data on aspirations were available from 34 countries (87.2%), those on initiated cycles were from 33 (or 32) countries (84.6 or 82.0%), both not necessarily the same countries. Only in 27 countries (69.2%) were we able to obtain information about both the number of initiated cycles and the number of oocyte collections.
Other countries have failed to report treatment endpoints, most notably delivery outcome data were availabe only in 39 countries after fresh cycles and after FER (97.4%). Underreporting of treatment numbers may lead to overestimation of the efficacy outcome of the offered treatments. Improvements in the quality of the retrieved data sets may still be achieved. This may possibly be achieved through the organization of external audits both in the offices of the national registries and in the local IVF clinics, as exemplified by Switzerland ( Van den Bergh et al., 2005) and by the European Liver Transplant register (Karam et al., 2003) . However, the introduction of such an external auditing system would require an enormous financial and logistic effort, which can only be performed successfully with support of the national and European authorities. The steady rise in the observed treatment numbers may be a motivation to improve stringency in the monitoring of the treatments. Whereas in 2013, 686 271 treatments with various forms of ART were reported to EIM , these numbers rose to 776 556 in 2014 (Table II) . Close to two-thirds of this increase results from a basic change in the Spanish registry, which now provides nearly complete data sets (78 182 treatments in 2013 to 109 275 treatments in 2014). In addition, the Russian centres contributed with 94 985 treatments in 2014 (in 2013: 67 861) . A total of 136 436 deliveries led to the birth of 170 163 infants, representing 2.1% of all children born in Europe (Table III) . Due to differences in access to ART, the relative proportion of children born after ART may vary from 0.2% in Serbia to 6.4% in Denmark. These numbers have a significant impact on demography and should therefore be of interest to all stakeholders.
Data collection can only be optimized in the presence of good governance. Compulsory data collection systems have been shown previously to be more effective than voluntary systems, but personal initiative still played a decisive role in seven countries. The countries with the lowest participation of IVF institutions were Serbia (1 of 18), Albania (1 of 8), Bulgaria (4 of 32), Croatia (7 of 13) and Ireland (3 of 7). Except in Croatia, none of these countries benefited from a compulsory data registration. Coherent and systematic data registration and monitoring of all treatment outcomes should become mandatory in ART and be considered as an indicator of excellent quality of care and good governance.
The annual EIM reports have been valuable to detect and monitor ongoing trends in ART. Whereas treatment numbers of IVF, IVM and FOR have appeared to be stable in recent years, those of ICSI, ED, FER and PGT have been on the rise. The predominance of ICSI over IVF has been observed in previous reports . The rise in treatment numbers with FER fits well to the current trend towards segmentation of ART (Devroey et al., 2011) including 'freeze all' cycles. This is the first report containing data on 'freeze all' cycles.
The steady rise in the demand for PGT may well be attributed to the availability of arays for genetic testing, with PGT-A numbers increasing from 4% in 2010 to 20% in 2013 (De Rycke et al., 2017 , and now replacing less effective forms of chromosome analysis, such as fluorescent in situ hybridization (Mastenbroek et al., 2007) . The report of the PGD consortium of ESHRE has demonstrated that the bulk of PGD consists of aneuploidy screening (De Rycke et al., 2017) and the demand/offer for that sort of treatment seems to be rising constantly, despite the current lack of prospective randomized clinical trials substantiating the benefits and specific indications for this technology (Sermon et al., 2016; Harper et al., 2018) .
Another trend visible from the annual EIM reports is the lower numbers of embryos transferred per treatment cycle resulting in fewer multiple deliveries. The number of embryo transfers with only one embryo continues to rise (Fig. 2) and, in parallel, the numbers of twin and triplet deliveries decline. Interestingly, whereas the proportion of premature deliveries of twins and triplets remains similar to previous years, the proportion of premature deliveries (<37 weeks) of singletons per embryo transfer has risen from 0.96% in 2006 to 1.79% in 2014 (Fig. 3) . The reason for this steady increase in premature singleton deliveries remains speculative, but all these findings point towards the need for continuous and prospective follow-up of all activities in ART.
Other severe adverse events, such as infection and haemorrhage complicating oocyte retrieval, but also maternal death, continue to occur. Three cases of maternal death were reported in 2014, all within the context of ongoing pregnancies (incidence rate: 1.59/100 000 pregnancies). The latter seem to be underreported, as an earlier Dutch survey has demonstrated a much higher incidence of maternal death within the context of ART. Indeed, an incidence of maternal mortality of 6/100 000 directly related to IVF and of 42.5/100 000 pregnancies resulting from ART, mainly in twin pregnancies (Braat et al. 2010 ) was reported. Underreporting of adverse events leads to an overestimation of the safety of the treatment. Although the number of reported foetal reductions has risen from 416 to 526 in 2014 (reported to be performed in 16 countries), these numbers most likely are also drastically underreported. Without this intervention, the number of high order multiple deliveries would be higher, but with current technology developments in ART (including elective single embryo transfer and cryostorage of remaining oocytes or embryos) multiple pregnancies and related complications should be avoidable today.
The practice of freezing oocytes and embryos is on the rise and that can be clearly seen in the steep rise of the number of recorded FER treatments, which in 2014 for the first time exceeded that of conventional IVF (i.e. 192 017 versus 146 148, Table I ). Earlier studies have shown that singleton newborns born from fresh treatments have lower birthweights than those born after a thawing cycle (De Geyter et al., 2006; Henningsen et al., 2011) . Recently, the incidence of neonates born large for gestational age has been shown to be significantly more prevalent in FER cycles (Pinborg et al., 2010 (Pinborg et al., , 2014 Luke et al., 2017) . Although the EIM data set cannot provide data on this particular potential adverse effect of ART, the EIM datasets will continue to monitor the relative importance of FER within the context of ART.
The EIM data sets also reveal large differences in access to infertility treatment in the various participating European countries. The World Health Organization (WHO) has defined 'infertility' as a 'disease of the reproductive system' and as a 'disability' and access to medical treatment has been issued as a human right. In contrast to those basic principles, the number of treatments with either form of ART varies greatly between European countries. This is best exemplified in those countries with complete coverage (Supplementary Table SIV) . Not only the number of cycles per million inhabitants varies between 423 in Malta and 2978 in Iceland, but also the relative number of infants born from ART treatments. The ESHRE Capri Group has estimated that~1500 couples with infertility per million inhabitants should be treated with ART per year (ESHRE Capri Group, 2001) . Even among the 14 countries with complete coverage five countries did not fulfil that requirement in 2014 (35.7%) and these countries might be thought to belong to the more advanced ones. Transparency in data both at the national level but also, for comparison purposes, at the international level may be particularly helpful in convincing politicians and health care authorities to undertake measures in improving access to treatment.
Until today the data collection handled by the EIM Consortium has been cross-sectional and based on annual data reporting. Cumulative data analysis has only been possible within the frame of 1 year. The EIM Consortium has come far to push the completeness of the European data collection beyond 90%, as first demonstrated in the 2014 data sets, described here. Increasingly, infertility treatments are being fragmented into small treatment units that may easily cross the time frame of crosssectional data collections, which points to the need for developing new surveillance tools. A concept for prospective follow-up of infertility treatment has therefore been elaborated earlier .
So far the annual reports published by the EIM consortium, including the present 18th report, have been limited to being purely descriptive. The organization of the data collection, as carried out by the EIM Consortium, may be further developed towards medical surveillance and vigilance. Surveillance is defined by the continuous and systematic collection of health data (here related to ART and its outcome) needed for the analysis and interpretation of trends in medical care with a special focus on safety. Surveillance in medical care goes far beyond considering the results of prospective randomized trials, in which very selected cohorts of patients are recruited and treated under well-controlled conditions. Register-based data have their value by being less biased by predefined selection criteria. They reflect to a much larger extent real-life conditions and for that reason have the capacity to give a more realistic picture of the outcome results. However, real surveillance can only be achieved with more or less complete data sets, in which underreporting is avoided. That goal can best be achieved if data submission to the national registries is made compulsory.
Medical surveillance may also be used for the establishment of vigilance. Vigilance aims at detecting serious or less serious adverse events resulting from medical activities. Through the increasing trend towards replacing fewer embryos per treatment cycle, present-day ART has been successful in reducing the incidence of multiple delivery and the EIM annual reports have been able to make this trend visible and this increases the awareness on the usefulness of such practice. In addition, a more novel development is the adoption of the principle of 'freeze all' and the delayed thawing and transfer of frozen embryos, which has already resulted in an upsurge of the number of FER cycles. All these trends are expected to lower the incidence of other common complications, such as OHSS and foetal reduction. Other adverse events may still occur and need to be registered, because vigilance does not only consist of merely recording adverse events, but also the assessment of underlying causes and proper understanding of the mechanisms leading to the adverse events, which ultimately may lead to the formulation of preventive measures as part of an ongoing quality management development.
As shown here, one in 50 children born in Europe are the result of ART treatments. Practitioners, professional bodies, and national and European political bodies have a duty to realize that such therapies require appropriate logistic and financial support in order to set up compulsory national reporting electronic databases, ideally a panEuropean centralized data collection, to monitor both the efficiency and safety of therapy and also the long-term health of children born after treatment. The creation of a unique individual patient European coding system will ensure all aspects of an ever increasing spectrum of ART care can be measured and analysed thus ensuring full surveillance and vigilance. The time is now. The concept of evolving the current cross-sectional register towards prospective surveillance and vigilance of care in ART will take years to become real and will require top down support from national and supranational health care authorities. Such a concept can only be supported by all stakeholders of ART, including the patients, and should be motivated to provide care with excellence.
